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Summary and Implications 
 Pigs were inoculated with virus-like replicon particle 
(VRP) vaccines expressing the influenza hemagglutinin 
(HA) protein. A robust antibody response was present 
following the inoculation. These results indicate that VRP 
vaccines can successfully express a foreign antigen in the 
pig and induce high antibody titers. This proof of concept 
work supports the further in vivo evaluation of VRP 
expressing swine influenza virus (SIV) HA protein as well 
as VRP co-expressing porcine reproductive and respiratory 
syndrome virus (PRRSV) GP5 and M proteins as novel 
vaccines for swine. 
 
Introduction 
 Virus-like replicon particles (VRP) derived from the 
alphavirus Venezuelan equine encephalitis (VEE) is a single 
cycle vector not capable of propagating past the initial cell 
infected (Figure 1). VRP have been previously used to show 
that co-expression of the GL and M proteins of equine 
arteritis virus are required for protection. We have recently 
developed VRP co-expressing GP5 and M proteins of 
PRRSV3, however there are no previous reports of 
immunizing swine with VRP vaccines. The purpose of this 
study was to determine the potential for using VRP vaccines 
in pigs. 
 
Materials and Methods 
 Pigs were obtained at 3 weeks of age and divided into 3 
groups of 4. On Day 0 (prime) and again on Day 14 (boost), 
pigs were vaccinated IM with 108 VRP/ml expressing the 
HA protein from A/Wyoming/03/2003 H3N2 (groups 1-2) 
or a control VRP (group 3). The VRP in group 1 were 
derived from VEE 3014 (wt strain) and group 2 from VEE 
TC-83 (vaccine strain). Serologic response to the HA 
protein was determined by hemagglutination-inhibition (HI) 
assay. 
 
Results and Discussion 
 Prior to vaccination all pigs were HI negative with a 
geometric mean titer (GMT) of 12 (Figure 2). Negative 
control pigs in group 3 remained negative through necropsy 
(GMT=20). An HI response was detected in group 1 
(GMT=67) and group 2 (GMT=56) following the priming 
dose. After the booster dose a strong HI response was 
detected in group 1 (GMT=2985) and group 2 (GMT=2985) 
with maximum titers reaching 1:5120. No difference in 
response was seen between groups 1 and 2 indicating that 
VRP derived from the non-select TC-83 vaccine strain can 
be used in future trials. These results indicate that VRP 
vaccines can successfully express a foreign antigen in the 
pig and induce high antibody titers. This proof of concept 
work supports the further in vivo evaluation of VRP 
expressing swine influenza virus (SIV) HA protein as well 
as VRP co-expressing PRRSV GP5 and M proteins as novel 
vaccines for swine. 
 
Figure 1. VEE VRP vaccine and packaging system. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. VEE Replicon Particle Vaccine and 
Packaging System 
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Figure 2: HI response of pigs to VRP expressing the 
influenza HA protein. A titer greater than 20 is 
considered protective. 
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